News Alert:

Cost-Utility Analysis for IBS Intervention: NHS Drug Tariff Application

22nd February 2024

The Challenge

The client had a novel product for use in patients with irritable bowel syndrome (IBS) and wished to have its product listed on the NHS Drug Tariff. To support the application, a health economic evaluation was required to demonstrate the relative cost-effectiveness of the intervention.

HTE’s approach

Our team worked with the client to review the results from a recently closed randomised controlled trial (RCT) of its product in patients with IBS. This review revealed information on disease progression and quality-adjusted life-years (QALYs) which we used to inform a Markov Model to simulate lifetime cost-effectiveness for the patient cohort assessed. The model was future-proofed by programming in adding additional potential benefits of the product such as a reduction in consultations and concomitant medication use. HTE supported the client by reviewing their dossier to NHS Prescription Services prior to submission.

The Outcome

The health economic evaluation demonstrated the cost-effectiveness of the product over a patient’s lifetime by showing an incremental cost-effectiveness ratio (ICER) which lies within the threshold applied by the NHS. The client’s application to NHS Prescription Services was successful and the product was accepted on to the Drug Tariff.

“Thank you for your invaluable help in allowing us to achieve a listing on the NHS Drug Tariff! We are very pleased and the Health Economic model for IBS helped enormously.” Research Director

Stay in Touch:

Keep up to date with all HTE news and events.

Subscribe to our mailing list